Pancreatic endocrine tumors

Modern Pathology

Volumn 24, Issue , 2011, Pages S66-S77

  Asa, Sylvia L ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Classification; Endocrine tumor; Molecular genetics; Pancreas; Predictive markers; Staging

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCAGON; INSULIN; MESSENGER RNA; SCATTER FACTOR RECEPTOR; SOMATOSTATIN;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; CHOLELITHIASIS; DIABETES MELLITUS; DISEASE SEVERITY; ENDOCRINE TUMOR; GASTRINOMA; GENE OVEREXPRESSION; GENETIC PREDISPOSITION; GLUCAGONOMA; HORMONE SYNTHESIS; HUMAN; IMMUNOHISTOCHEMISTRY; INSULINOMA; MEN SYNDROME TYPE 1; NEUROFIBROMATOSIS; NOMENCLATURE; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SOMATOSTATINOMA; TUBEROUS SCLEROSIS; TUMOR CLASSIFICATION; VHL DISEASE;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; ISLETS OF LANGERHANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTORS, SOMATOSTATIN; TERMINOLOGY AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 79953309273     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.127     Document Type: Article

References (69)

1. DeLellis RA, Tischler AS. The dispersed neuroendocrine cell system In: Kovacs K, Asa SL (eds). Functional Endocrine Pathology. Blackwell: Boston, 1998, pp 529-549.
2. Oberndorfer S. Karzinoide tumoren des dünndarms. Frankfurter Zeitschrift für Pathologie 1907;1:425-432.
3. Kloppel G, Rindi G, Anlauf M, et al. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007;451 (Suppl 1):S9-S27.
4. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004;1014: 13-27.
5. DeLellis RA, Lloyd RV, Heitz PU, et al. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press: Lyons, France, 2004.
6. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005; 19:753-781.
7. Grimelius L, Hultquist GT, Stenkvist B. Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch A Pathol Anat Histol 1975;365:275-288.
8. Hruban RH, Pitman MB, Klimstra DS. Tumors of the Pancreas 4th Series, Fascicle 6 ed. Armed Forces Institute of Pathology: Washington, DC, 2007.
9. Chetty R, Asa SL, Adsay NV. Pancreatic endocrine tumors with ductules. Am J Surg Pathol 2005;29: 136-137.
10. Chetty R, Serra S, Asa SL, et al. Pancreatic endocrine tumour with ductules: further observations of an unusual histological subtype. Pathol 2006;38:5-9.
11. Serra S, Asa SL, Chetty R. Intracytoplasmic inclusions (including the so-called ‘rhabdoid’ phenotype) in pancreatic endocrine tumors. Endocr Pathol 2006;17:75-81.
12. Chetty R, Asa SL. Pancreatic endocrine tumour with cytoplasmic keratin whorls. Is the term ‘rhabdoid’ appropriate? J Clin Pathol 2004;57:1106-1110.
13. Asa SL, Ezzat S. Endocrine organs In: Allison MR (ed). The Cancer Handbook. John Wiley and Sons Ltd: West Sussex, England, 2007, pp 611-623.
14. Eriksson B, Arnberg H, Oberg K, et al. Chromogranins— new sensitive markers for neuroendocrine tumors. Acta Oncol 1989;28:325-329.
15. Tanimoto A, Matsuki Y, Tomita T, et al. Histidine decarboxylase expression in pancreatic endocrine cells and related tumors. Pathol Int 2004;54: 408-412.
16. Srivastava A, Padilla O, Fischer-Colbrie R, et al. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids. Am J Surg Pathol 2004; 28:1371-1378.
17. Wick MR. Neuroendocrine neoplasia. Current concepts. Am J Clin Pathol 2000;113:331-335.
18. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996;429:323-333.
19. Ekeblad S, Skogseid B, Dunder K, et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008;14:7798-7803.
20. Kloppel G, Couvelard A, Perren A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009;90:162-166.
21. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395-401.
22. Fischer L, Kleeff J, Esposito I, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008;95:627-635.
23. Edge SB, Byrd DR, Carducci MA, et al. AJCC Cancer Staging Manual 7 edn. Springer: New York, NY, 2009.
24. Murphy D, Bishop A, Rindi G, et al. Mice transgenic for a vasopressin-SV40 hybrid oncogene develop tumors of the endocrine pancreas and the anterior pituitary: a possible model for human multiple endocrine neoplasia type 1. Am J Pathol 1987;129:552-566.
25. Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res (Baltimore) 1997;57:4682-4686.
26. Toliat M, Berger W, Ropers HH, et al. Mutations in the MEN1 gene in sporadic neuroendocrine tumours of gastroenteropancreatic system. Lancet 1997;350: 1223.
27. Debelenko LV, Zhuang Z, Emmert-Buck MR, et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 1997;57:2238-2243.
28. Hessman O, Lindberg D, Skogseid B, et al. Mutation of the multiple endocrine neoplasia type 1 gene in nonfamilial, malignant tumors of the endocrine pancreas. Cancer Res 1998;58:377-379.
29. Maioli M, Ciccarese M, Pacifico A, et al. Familial insulinoma: description of two cases. Acta Diabetol 1992;29:38-40.
30. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type1. Science 1997;276:404-407.
31. Agarwal SK, Kester MB, Debelenko LV, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997;6:1169-1175.
32. Lubensky IA. Endocrine Pancreas In: LiVolsi VA, Asa SL (eds). Endocrine Pathology. Churchill Livingstone: Philadelphia, PA, 2002, pp 205-235.
33. Kovacs K, Horvath E, Asa SL, et al. Microscopic peliosis of pancreatic islets in a woman with MEN-1 syndrome. Arch Pathol Lab Med 1986;110:607-610.
34. Asa SL, Singer W, Kovacs K, et al. Pancreatic endocrine tumour producing growth hormone-releasing hormone associated with multiple endocrine neoplasia type I syndrome. Acta Endocrinol (Copenh) 1987;115:331-337.
35. Asa SL. The endocrine pancreas and its tumors. Endocr Pathol 1993;4:120-130.
36. Hessman O, Lindberg D, Einarsson A, et al. Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1-associated pancreatic endocrine tumors. Genes Chromosomes Cancer 1999;26:258-264.
37. Hessman O, Skogseid B, Westin G, et al. Multiple allelic deletions and intratumoral genetic heterogeneity in men1 pancreatic tumors. J Clin Endocrinol Metab 2001;86:1355-1361.
38. Kaelin Jr WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673-682.
39. Lubensky IA, Pack S, Ault D, et al. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 1998;153:223-231.
40. Hammel PR, Vilgrain V, Terris B, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d’Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000;119:1087-1095.
41. Chetty R, Kennedy M, Ezzat S, et al. Pancreatic endocrine pathology in von Hippel-Lindau disease: an expanding spectrum of lesions. Endocr Pathol 2004;15:141-148.
42. Chetty R, Ezzat S, Asa SL. Microadenomatosis of the pancreas in von Hippel-Lindau disease. Am J Surg Pathol 2006;30:1630-1631.
43. Xu GF, O’Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990;62:599-608.
44. Ballester R, Marchuk D, Boguski M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990;63: 851-859.
45. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 2007;6:340-351.
46. Mao C, Shah A, Hanson DJ, et al. Von Recklinghausen’s disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 1995;59:67-73.
47. Jensen RT, Berna MJ, Bingham DB, et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008;113(7 Suppl):1807-1843.
48. Verhoef S, Diemen-Steenvoorde R, Akkersdijk WL, et al. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr 1999;158:284-287.
49. Francalanci P, Diomedi-Camassei F, Purificato C, et al. Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. Am J Surg Pathol 2003; 27:1386-1389.
50. Kim H, Kerr A, Morehouse H. The association between tuberous sclerosis and insulinoma. AJNR Am J Neuroradiol 1995;16:1543-1544.
51. Eledrisi MS, Stuart CA, Alshanti M. Insulinoma in a patient with tuberous sclerosis: is there an association? Endocr Pract 2002;8:109-112.
52. Schwarzkopf G, Pfisterer J. Metastasizing gastrinoma and tuberous sclerosis complex. Association or coincidence? Zentralbl Pathol 1994;139:477-481.
53. Plank TL, Logginidou H, Klein-Szanto A, et al. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1-and TSC2-linked angiomyolipomas. Mod Pathol 1999;12: 539-545.
54. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450-482.
55. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002;440:461-475.
56. Peghini PL, Iwamoto M, Raffeld M, et al. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 2002;8:2273-2285.
57. Deshpande V, Fernandez-del Castillo C, Muzikansky A, et al. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 2004;28:1145-1153.
58. Ali A, Serra S, Asa SL, et al. The predictive value of CK19 and CD99 in pancreatic endocrine tumors. Am J Surg Pathol 2006;30:1588-1594.
59. Schmitt AM, Anlauf M, Rousson V, et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 2007;31:1677-1682.
60. Chetty R, Serra S, Asa SL. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors. Am J Surg Pathol 2008;32:413-419.
61. Serra S, Asa SL, Bamberger AM, et al. CEACAM1 expression in pancreatic endocrine tumors. Appl Immunohistochem Mol Morphol 2009;17:286-293.
62. Evers BM, Rady PL, Sandoval K, et al. Gastrinomas demonstrate amplification of the HER-2/neu protooncogene. Ann Surg 1994;219:596-601.
63. Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002;62: 840-847.
64. Streit S, Bange J, Fichtner A, et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004;111:213-217.
65. Thussbas C, Nahrig J, Streit S, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006;24: 3747-3755.
66. Serra S, Zheng L, Ezzat S, et al. The FGFR4-R388 transmembrane polymorphism preferentially recruits cSrc to constitutively activate STAT3 in promoting pancreatic neuroendocrine tumor metastasis (submitted).
67. Cavallaro U, Niedermeyer J, Fuxa M, et al. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol 2001;3:650-657.
68. Modlin IM, Moss SF, Chung DC, et al. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008; 100:1282-1289.
69. Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National LongitudinalMortality Study. Cancer Causes Control 2009;20:417-435.